Lauren M Pachman

List of Publications by Year
in descending order

172	9,870	28274 55	40979 93
papers	citations	h-index	g-index

183	183	183	5390
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet, The, 2008, 371, 2201-2212.	13.7	383
2	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology, 2004, 43, 49-54.	1.9	311
3	US incidence of juvenile dermatomyositis, 1995-1998: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis and Rheumatism, 2003, 49, 300-305.	6.7	304
4	Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis and Rheumatism, 1985, 28, 1367-1376.	6.7	295
5	Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rbâ€“MyoD pathways in muscle regeneration. Brain, 2006, 129, 996-1013.	7.6	288
6	TNFÎ±-308A allele in juvenile dermatomyositis: Association with increased production of tumor necrosis factor Î±, disease duration, and pathologic calcifications. Arthritis and Rheumatism, 2000, 43, 2368-2377.	6.7	238
7	Mutations in the Mu Heavy-Chain Gene in Patients with Agammaglobulinemia. New England Journal of Medicine, 1996, 335, 1486-1493.	27.0	234
8	Combined immunodeficiency disease associated with adenosine deaminase deficiency. Journal of Pediatrics, 1975, 86, 169-181.	1.8	226
9	Gene Expression Profiling in DQA1*0501+ Children with Untreated Dermatomyositis: A Novel Model of Pathogenesis. Journal of Immunology, 2002, 168, 4154-4163.	0.8	220
10	Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. British Journal of Rheumatology, 2003, 42, 1452-1459.	2.3	209
11	Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care and Research, 2010, 62, 465-472.	3.4	204
12	Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP). American Journal of Medicine, 1982, 73, 49-56.	1.5	197
13	Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II. The childhood myositis assessment scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis and Rheumatism, 1999, 42, 2213-2219.	6.7	194
14	Disease activity score for children with juvenile dermatomyositis: Reliability and validity evidence. Arthritis and Rheumatism, 2003, 49, 7-15.	6.7	190
15	PREVALENCE OF COXSACKIE B VIRUS ANTIBODIES IN PATIENTS WITH JUVENILE DERMATOMYOSITIS. Arthritis and Rheumatism, 1986, 29, 1365-1370.	6.7	181
16	Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis and Rheumatism, 2009, 60, 3413-3424.	6.7	170
17	Juvenile dermatomyositis: A clinical and immunologic study. Journal of Pediatrics, 1980, 96, 226-234.	1.8	138
18	History of infection before the onset of juvenile dermatomyositis: Results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis and Rheumatism, 2005, 53, 166-172.	6.7	130

#	Article	IF	Citations
19	Persistent association of nailfold capillaroscopy changes and skin involvement over thirtyâ€six months with duration of untreated disease in patients with juvenile dermatomyositis. Arthritis and Rheumatism, 2008, 58, 571-576.	6.7	128
20	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Annals of the Rheumatic Diseases, 2016, 75, 1558-1566.	0.9	127
21	Duration of illness is an important variable for untreated children with juvenile dermatomyositis. Journal of Pediatrics, 2006, 148, 247-253.	1.8	125
22	Elevated serum interferonâ€Î± activity in juvenile dermatomyositis: Associations with disease activity at diagnosis and after thirtyâ€six months of therapy. Arthritis and Rheumatism, 2009, 60, 1815-1824.	6.7	119
23	Genomeâ€Wide Association Study of Dermatomyositis Reveals Genetic Overlap With Other Autoimmune Disorders. Arthritis and Rheumatism, 2013, 65, 3239-3247.	6.7	113
24	Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis and Rheumatism, 2009, 60, 3425-3435.	6.7	107
25	Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. Journal of Pediatrics, 1992, 120, 468-473.	1.8	106
26	Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes and Immunity, 2015, 16, 470-480.	4.1	103
27	Juvenile Dermatomyositis: Pathophysiology and Disease Expression. Pediatric Clinics of North America, 1995, 42, 1071-1098.	1.8	97
28	A broadened spectrum of juvenile myositis. myositis-specific autoantibodies in children. Arthritis and Rheumatism, 1994, 37, 1534-1538.	6.7	96
29	Abnormalities in serum osteocalcin values in children with chronic rheumatic diseases. Journal of Pediatrics, 1990, 116, 574-580.	1.8	93
30	Fgfr4 Is Required for Effective Muscle Regeneration in Vivo. Journal of Biological Chemistry, 2006, 281, 429-438.	3.4	90
31	Pustulosis palmaris et plantaris: Its association with chronic recurrent multifocal osteomyelitis. Journal of the American Academy of Dermatology, 1985, 12, 927-930.	1.2	84
32	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care and Research, 2010, 62, 1533-1541.	3.4	84
33	Fatal Lymphoma after Transplantation of Cultured Thymus in Children with Combined Immunodeficiency Disease. New England Journal of Medicine, 1979, 301, 565-568.	27.0	81
34	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.9	81
35	Molecular genetic studies of major histocompatibility complex genes in children with Juvenile dermatomyositis: Increased risk associated with HLA-DQA1â^—0501. Human Immunology, 1991, 32, 235-240.	2.4	80
36	MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: Association with muscle involvement. Clinical Immunology, 2006, 120, 319-325.	3.2	79

#	Article	IF	Citations
37	Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis and Rheumatism, 2008, 59, 222-226.	6.7	78
38	Mycophenolate mofetil: A possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care and Research, 2010, 62, 1446-1451.	3.4	78
39	Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care and Research, 2010, 62, 219-225.	3.4	77
40	Intralipid alterations in pulmonary prostaglandin metabolism and gas exchange. Critical Care Medicine, 1983, 11, 794-798.	0.9	76
41	Familial Aggregation of Autoimmune Disease in Juvenile Dermatomyositis. Pediatrics, 2011, 127, e1239-e1246.	2.1	74
42	Composition of calcifications in children with juvenile dermatomyositis: Association with chronic cutaneous inflammation. Arthritis and Rheumatism, 2006, 54, 3345-3350.	6.7	71
43	Immunogenetic studies of juvenile dermatomyositis: hla-dr antigen frequencies. Arthritis and Rheumatism, 1983, 26, 214-216.	6.7	68
44	Evaluation of a psychological treatment package for treating pain in juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1992, 5, 101-110.	6.7	68
45	Pharmacokinetic studies of prednisolone in children. Journal of Pediatrics, 1978, 93, 299-303.	1.8	67
46	Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. Journal of Rheumatology, 2004, 31, 1644-9.	2.0	65
47	Torg Syndrome Is Caused by Inactivating Mutations in MMP2 and Is Allelic to NAO and Winchester Syndrome. Journal of Bone and Mineral Research, 2006, 22, 329-333.	2.8	63
48	Expression of TNFÎ± by Muscle Fibers in Biopsies from Children with Untreated Juvenile Dermatomyositis: Association with the TNFÎ±-308A Allele. Clinical Immunology, 2001, 100, 236-239.	3.2	62
49	Repair of osteopenia in children with juvenile rheumatoid arthritis. Journal of Pediatrics, 1993, 122, 693-696.	1.8	61
50	New-onset juvenile dermatomyositis. Comparisons with a healthy cohort and children with juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1997, 40, 1526-1533.	6.7	61
51	The effect of salicylate on the metabolism of normal and stimulated human lymphocytes in vitro. Journal of Clinical Investigation, 1971, 50, 226-230.	8.2	61
52	Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis and Rheumatism, 2010, 62, 2813-2822.	6.7	60
53	Autoantibodies to DEK oncoprotein in human inflammatory disease. Arthritis and Rheumatism, 2000, 43, 85-93.	6.7	59
54	Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunology, 2008, 9, 43.	2.2	59

#	Article	IF	Citations
55	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 911-923.	5.6	59
56	A New Complication of Stem Cell Transplantation: Measles Inclusion Body Encephalitis. Pediatrics, 2004, 114, e657-e660.	2.1	58
57	25-Hydroxyvitamin D therapy in children with active juvenile rheumatoid arthritis: Short-term effects on serum osteocalcin levels and bone mineral density. Journal of Pediatrics, 1991, 119, 657-660.	1.8	57
58	Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity. Journal of Pediatrics, 2018, 195, 16-27.	1.8	57
59	Self epitopes shared between human skeletal myosin andStreptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis and Rheumatism, 2002, 46, 3015-3025.	6.7	55
60	Clinical Status and Cardiovascular Risk Profile of Adults with a History of Juvenile Dermatomyositis. Journal of Pediatrics, 2011, 159, 795-801.	1.8	55
61	Pilot Study of Etanercept in Patients With Refractory Juvenile Dermatomyositis. Arthritis Care and Research, 2014, 66, 783-787.	3.4	53
62	Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays. Rheumatic Disease Clinics of North America, 2002, 28, 743-757.	1.9	52
63	The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: A propensity score analysis. Arthritis and Rheumatism, 2008, 59, 989-995.	6.7	52
64	Juvenile dermatomyositis: The association of the TNFÎ±-308A Allele and disease chronicity. Current Rheumatology Reports, 2001, 3, 379-386.	4.7	50
65	Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis. Arthritis and Rheumatology, 2020, 72, 348-358.	5.6	50
66	Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases. Pediatric Rheumatology, 2019, 17, 61.	2.1	48
67	GAMMA-carboxyglutamate excretion and calcinosis in juvenile dermatomyositis. Arthritis and Rheumatism, 1982, 25, 1094-1100.	6.7	47
68	Immunogenetic studies of juvenile dermatomyositis. III. Study of antibody to organ-specific and nuclear antigens. Arthritis and Rheumatism, 1985, 28, 151-157.	6.7	47
69	Juvenile dermatomyositis: immunogenetics, pathophysiology, and disease expression. Rheumatic Disease Clinics of North America, 2002, 28, 579-602.	1.9	47
70	Conceptions of Illness by Children with Juvenile Rheumatoid Arthritis: A Cognitive Developmental Approach. Journal of Pediatric Psychology, 1993, 18, 83-97.	2.1	46
71	Lack of detection of enteroviral rna or bacterial dna in magnetic resonance imagingâ€“directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis. Arthritis and Rheumatism, 1995, 38, 1513-1518.	6.7	46
72	Development of a Rapid Whole Blood Flow Cytometry Procedure for the Diagnosis of X-Linked Hyper-IgM Syndrome Patients and Carriers. Clinical Immunology and Immunopathology, 1997, 85, 172-181.	2.0	46

#	Article	IF	Citations
73	Environmental factors associated with disease flare in juvenile and adult dermatomyositis. Rheumatology, 2017, 56, 1342-1347.	1.9	46
74	RANKL:Osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis and Rheumatism, 2007, 56, 977-983.	6.7	45
75	Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. Journal of Rheumatology, 2008, 35, 927-9.	2.0	44
76	Psychological Factors Affecting Reported Pain in Juvenile Rheumatoid Arthritis. Journal of Pediatric Psychology, 1993, 18, 561-573.	2.1	43
77	Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis. Arthritis and Rheumatology, 2016, 68, 761-768.	5.6	43
78	Juvenile Dermatomyositis Presenting With Rash Alone. Pediatrics, 1997, 100, 391-391.	2.1	41
79	Increased Plasma Thrombospondin-1 (TSP-1) Levels Are Associated with the TNFÎ±-308A Allele in Children with Juvenile Dermatomyositis. Clinical Immunology, 2002, 103, 260-263.	3.2	41
80	Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miRâ€126. Arthritis and Rheumatism, 2012, 64, 3809-3817.	6.7	40
81	Evidence for intravascular coagulation in systemic onset, but not polyarticular, juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1985, 28, 256-261.	6.7	39
82	Serum Neopterin Levels as a Diagnostic Marker of Hemophagocytic Lymphohistiocytosis Syndrome. Vaccine Journal, 2011, 18, 609-614.	3.1	39
83	Juvenile Dermatomyositis. Pediatric Clinics of North America, 1986, 33, 1097-1117.	1.8	38
84	Brief Report: Interferonâ€Î± Induction and Detection of Antiâ€Ro, Antiâ€La, Antiâ€Sm, and Antiâ€RNP Autoantibodies by Autoantigen Microarray Analysis in Juvenile Dermatomyositis. Arthritis and Rheumatism, 2013, 65, 2424-2429.	6.7	37
85	Decreased Levels of CD54 (ICAM-1)-Positive Lymphocytes in the Peripheral Blood in Untreated Patients with Active Juvenile Dermatomyositis. Vaccine Journal, 2000, 7, 693-697.	2.6	36
86	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Annals of the Rheumatic Diseases, 2018, 77, 241-250.	0.9	36
87	Cor Pulmonale Secondary to Upper Airway Obstruction. Chest, 1975, 68, 166-171.	0.8	35
88	HLA-B8 IN JUVENILE DERMATOMYOSITIS. Lancet, The, 1977, 310, 567-568.	13.7	34
89	Gene-Gene-Sex Interaction in Cytokine Gene Polymorphisms Revealed by Serum Interferon Alpha Phenotype in Juvenile Dermatomyositis. Journal of Pediatrics, 2010, 157, 653-657.	1.8	33
90	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteriaâ€"methodological aspects. Rheumatology, 2017, 56, 1884-1893.	1.9	33

#	Article	IF	Citations
91	Pharmacokinetic monitoring of salicylate therapy in children with juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1979, 22, 826-831.	6.7	31
92	Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis. Current Rheumatology Reports, 2006, 8, 236-243.	4.7	31
93	Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis. Arthritis and Rheumatism, 2010, 62, 1533-1538.	6.7	31
94	Immunogenetic studies of juvenile dermatomyositis. Tissue Antigens, 1983, 21, 45-49.	1.0	29
95	Juvenile dermatomyositis calcifications selectively displayed markers of bone formation. Arthritis and Rheumatism, 2009, 61, 501-508.	6.7	29
96	The lack of effect of transfer factor in thymic dysplasia with immunoglobulin synthesis. Journal of Pediatrics, 1974, 84, 681-688.	1.8	28
97	Characterization of Dystrophic Calcification Induced in Mice by Cardiotoxin. Calcified Tissue International, 2009, 85, 267-275.	3.1	28
98	Vitamin D metabolism in rats with adjuvant-induced arthritis. Journal of Bone and Mineral Research, 1990, 5, 905-913.	2.8	28
99	An update on juvenile dermatomyositis. Current Opinion in Rheumatology, 1995, 7, 437-441.	4.3	27
100	The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis and Rheumatism, 2000, 13, 360-368.	6.7	27
101	Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: Impact of duration of untreated disease. Clinical Immunology, 2007, 125, 165-172.	3.2	27
102	Methylation alterations of WT1 and homeobox genes in inflamed muscle biopsy samples from patients with untreated juvenile dermatomyositis suggest selfâ€renewal capacity. Arthritis and Rheumatism, 2012, 64, 3478-3485.	6.7	27
103	Risk of Coronary Abnormalities due to Kawasaki Disease in Urban Area With Small Asian Population. JAMA Pediatrics, 1987, 141, 420.	3.0	26
104	Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis. Arthritis and Rheumatology, 2020, 72, 1214-1226.	5.6	26
105	Correction of neutropenia and hypogammaglobulinemia in X-linked hyper-IgM syndrome by allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1998, 22, 1215-1218.	2.4	24
106	Torg osteolysis syndrome. , 1998, 80, 207-212.		24
107	Pathological Calcification in Juvenile Dermatomyositis (JDM): MicroCT and Synchrotron X-Ray Diffraction Reveal Hydroxyapatite with Varied Microstructures. Connective Tissue Research, 2004, 45, 248-256.	2.3	24
108	Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. Steroids, 2018, 140, 159-166.	1.8	24

#	Article	IF	Citations
109	Juvenile Dermatomyositis and Polymyositis. Clinics in Rheumatic Diseases, 1984, 10, 95-115.	1.3	24
110	INFLAMMATORY MYOPATHY IN CHILDREN. Rheumatic Disease Clinics of North America, 1994, 20, 919-942.	1.9	22
111	Double Trouble. Archives of Dermatology, 2011, 147, 831.	1.4	21
112	Serum protein biomarkers for juvenile dermatomyositis: a pilot study. BMC Rheumatology, 2020, 4, 52.	1.6	21
113	Liposyn infusion increases plasma prostaglandin concentrations. Pediatric Pulmonology, 1986, 2, 154-158.	2.0	20
114	Connective tissue disease registries. Arthritis and Rheumatism, 1997, 40, 1556-1559.	6.7	20
115	Cytokines in juvenile dermatomyositis pathophysiology: potential and challenge. Current Opinion in Rheumatology, 2003, 15, 691-697.	4.3	20
116	Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy. Current Treatment Options in Rheumatology, 2021, 7, 39-62.	1.4	20
117	Flow cytometric analyses of the lymphocyte subsets in peripheral blood of children with untreated active juvenile dermatomyositis. Vaccine Journal, 1995, 2, 205-208.	2.6	20
118	Ovarian Teratoma Mimicking Features of Juvenile Dermatomyositis in a Child. Pediatrics, 2011, 128, e1293-e1296.	2.1	19
119	MicroRNA-10a Regulation of Proinflammatory Mediators: An Important Component of Untreated Juvenile Dermatomyositis. Journal of Rheumatology, 2016, 43, 161-168.	2.0	18
120	Immunological findings in familial juvenile endocrine deficiency syndrome associated with mucocutaneous candidiasis. American Journal of the Medical Sciences, 1971, 261, 213-218.	1.1	18
121	Dysregulated NK cell PLCÎ³2 signaling and activity in juvenile dermatomyositis. JCI Insight, 2018, 3, .	5.0	18
122	INCREASED FREQUENCY OF HLA-B8 IN JUVENILE DERMATOMYOSITIS. Lancet, The, 1977, 310, 1238.	13.7	17
123	Relationship between saliva salicylate concentration and free or total salicylate concentration in serum of children with juvenile rheumatoid arthritis. Clinical Pharmacology and Therapeutics, 1980, 27, 619-627.	4.7	16
124	Four-year-olds, healthy or recovering from Juvenile Dermatomyositis, do not achieve a full score on the Childhood Myositis Assessment Scale (CMAS). Arthritis Care and Research, 2013, 65, NA-NA.	3.4	16
125	Pulmonary Function Tests in Idiopathic Inflammatory Myopathy: Association With Clinical Parameters in Children. Arthritis Care and Research, 2013, 65, 1424-1431.	3.4	15
126	IgA deficiency and recurrent pneumonia in the Schwartz-Jampel syndrome. Journal of Pediatrics, 1976, 88, 1060-1061.	1.8	14

#	Article	IF	Citations
127	PMN chemotactic inhibition associated with a cryoglobulin. Journal of Pediatrics, 1977, 90, 225-229.	1.8	14
128	Skin disease is more recalcitrant than muscle disease: A long-term prospective study of 184 children with juvenile dermatomyositis. Journal of the American Academy of Dermatology, 2021, 84, 1610-1618.	1.2	14
129	Validity of reported pain as a measure of clinical state in juvenile rheumatoid arthritis.. Annals of the Rheumatic Diseases, 1989, 48, 817-819.	0.9	13
130	Association among SomaticHPRTMutant Frequency, Peripheral Blood T-Lymphocyte Clonality, and Serologic Parameters of Disease Activity in Children with Juvenile Onset Dermatomyositis. Clinical Immunology, 1999, 91, 61-67.	3.2	13
131	Comparison of Lesional Juvenile Myositis and Lupus Skin Reveals Overlapping Yet Unique Disease Pathophysiology. Arthritis and Rheumatology, 2021, 73, 1062-1072.	5.6	13
132	The early involvement of pulmonary prostaglandins in hyperoxic lung injury. Prostaglandins, Leukotrienes, and Medicine, 1986, 25, 105-122.	0.7	12
133	Cryoprecipitates in Kawasaki syndrome. Pediatric Infectious Disease Journal, 1988, 7, 255-257.	2.0	12
134	Studies of 96 children with Juvenile Dermatomyositis: P155/140, is associated with loss of nailfold capillaries, but not generalized lipodystrophy. Arthritis Care and Research, 2020, , .	3.4	12
135	Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive. Scientific Reports, 2022, 12, 275.	3.3	12
136	Chronic neutropenia: Response to plasma with high colony-stimulating activity. Journal of Pediatrics, 1975, 87, 713-719.	1.8	10
137	Gene Selection for Multiclass Prediction by Weighted Fisher Criterion. Eurasip Journal on Bioinformatics and Systems Biology, 2007, 2007, 1-15.	1.4	10
138	Clues to Disease Activity in Juvenile Dermatomyositis: Neopterin and Other Biomarkers. Diagnostics, 2022, 12, 8.	2.6	10
139	Autoantibody to PL-12 (Anti-Alanyl-tRNA Synthetase) in an African American Girl with Juvenile Dermatomyositis and Resolution of Interstitial Lung Disease. Journal of Rheumatology, 2011, 38, 394-395.	2.0	9
140	Association with HLA-DRÎ²1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. Human Molecular Genetics, 2022, 31, 2471-2481.	2.9	9
141	Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study. Pediatric Rheumatology, 2017, 15, 42.	2.1	8
142	Decreased CD3-CD16+CD56+ natural killer cell counts in children with orbital myositis: a clue to disease activity. RMD Open, 2017, 3, e000385.	3.8	7
143	Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study. BMC Rheumatology, 2022, 6, 36.	1.6	7
144	Occult lupus nephropathy: a correlated light, electron and immunofluorescent microscopic study. Histopathology, 1977, 1, 401-419.	2.9	6

#	Article	IF	Citations
145	Synovial fluid in seronegative juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1980, 23, 1256-1261.	6.7	6
146	A Mouse Model of Human Primitive Neuroectodermal Tumors Resulting from Microenvironmentally-Driven Malignant Transformation of Orthotopically Transplanted Radial Glial Cells. PLoS ONE, 2015, 10, e0121707.	2.5	6
147	Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography. Pediatric Rheumatology, 2016, 14, 64.	2.1	6
148	Changes in total body fat and body mass index among children with juvenile dermatomyositis treated with high-dose glucocorticoids. Pediatric Rheumatology, 2021, 19, 118.	2.1	6
149	Oleic acid lung injury increases plasma prostaglandin levels. Prostaglandins Leukotrienes and Essential Fatty Acids, 1989, 35, 157-164.	2.2	5
150	ATYPICAL PNEUMOCYSTIS CARINII PNEUMONIA IN A CHILD WITH HYPER-IgM SYNDROME. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1998, 18, 71-78.	0.3	5
151	Juvenile Dermatomyositis: A Clinical Overview. Pediatrics in Review, 1990, 12, 117-124.	0.4	5
152	The effects of sodium salicylate on the anamnestic immune response in vitro. Experientia, 1971, 27, 924-925.	1.2	4
153	Hemiallogeneic bone marrow transplantation in a child with severe combined immunodeficiency disease. Journal of Pediatrics, 1972, 80, 441-449.	1.8	4
154	Symptomatic hypothyroidism in children with collagen disease. Journal of Pediatrics, 1975, 87, 82-84.	1.8	4
155	Primary immunodeficiency in children: An update. Current Problems in Pediatrics, 1989, 19, 7-64.	1.1	4
156	Calcification in a Case of Circumscribed Myositis Ossificans: Figure 1.. Journal of Rheumatology, 2010, 37, 876-876.	2.0	4
157	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. Arthritis Research and Therapy, 2016, 18, 156.	3.5	4
158	IgG and IgA autoantibodies against L1 ORF1p expressed in granulocytes correlate with granulocyte consumption and disease activity in pediatric systemic lupus erythematosus. Arthritis Research and Therapy, 2021, 23, 153.	3.5	4
159	The effect of parenteral alimentation fluid, undiluted or diluted with saline or frseh sera, on the growth of Candida albicans in vitro at 37 ï¿½C. Mycopathologia, 1975, 55, 65-69.	3.1	3
160	Effect of Sodium Salicylate on Hamster Cells in vitro. Journal of Pharmaceutical Sciences, 1976, 65, 756-758.	3.3	3
161	ACTIVE JUVENILE DERMATOMYOSITIS (JDMS) IS ASSOCIATED WITH COMPLEMENT AND COAGULATION ACTIVATION, AND INCREASED TITERS TO ANTINUCLEAR (ANA) AND COXSACKIE B VIRAL (COX-B) ANTIGENS. Pediatric Research, 1984, 18, 262A-262A.	2.3	3
162	Leishmaniasis mimicking new-onset juvenile dermatomyositis: Comment on the article by Pachman et al. Arthritis and Rheumatism, 1998, 41, 1139-1140.	6.7	3

#	Article	IF	Citations
163	Nailfold Capillaroscopy as a Biomarker in the Evaluation of Pediatric Inflammatory Bowel Disease. Crohn's & Colitis 360, 2021, 3, otab069.	1.1	3
164	SUPPRESSION OF LYMPHOCYTE TRANSFORMATION BY ASPIRIN. Lancet, The, 1973, 302, 1212-1213.	13.7	2
165	Increase in serum concentration of keratan sulfate after treatment of growth hormone deficiency with growth hormone. Journal of Pediatrics, 1990, 116, 400-403.	1.8	2
166	Juvenile Dermatomyositis and Other Inflammatory Myopathies in Children. , 2015, , 834-881.		2
167	Clinical description and epidemiology data. Clinical Immunology Newsletter, 1998, 18, 105-118.	0.1	1
168	Juvenile Dermatomyositis. Pediatrics, 1999, 103, 194-194.	2.1	1
169	Pathological calcifications studied with micro-CT. , 2004, , .		1
170	Granuloma annulare. Arthritis and Rheumatism, 1987, 30, 117-119.	6.7	0
171	AtypicalPneumocystis CariniiPneumonia in a Child with Hyper-IgM Syndrome. Fetal and Pediatric Pathology, 1998, 18, 71-78.	0.3	0
172	Juvenile Dermatomyositis. , 2009, , 55-86.		0